Novo Nordisk EBITDA 2010-2024 | NVO

Novo Nordisk EBITDA for the quarter ending September 30, 2024 was $5.339B, a 24.23% increase year-over-year.

  • Novo Nordisk 2023 EBITDA was 16.261B, a 39.75% increase from 2022.
  • Novo Nordisk 2022 EBITDA was 11.635B, a 13.09% increase from 2021.
  • Novo Nordisk 2021 EBITDA was 10.289B, a 12.16% increase from 2020.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.

Novo Nordisk EBITDA 2010-2024 | NVO

  • Novo Nordisk 2023 EBITDA was 16.261B, a 39.75% increase from 2022.
  • Novo Nordisk 2022 EBITDA was 11.635B, a 13.09% increase from 2021.
  • Novo Nordisk 2021 EBITDA was 10.289B, a 12.16% increase from 2020.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company NameMarket
Cap
Eli Lilly (LLY)$692.7B
Johnson & Johnson (JNJ)$368.4B
AbbVie (ABBV)$294.4B
Merck (MRK)$244.2B
Novartis AG (NVS)$211.1B
AstraZeneca (AZN)$197.8B
Pfizer (PFE)$142.2B
Sanofi (SNY)$121.8B
Innoviva (INVA)$1.2B